.jpg)
PROTEIN TYROSINE PHOSPHATASES AS BIOMARKERS FOR HEPATOCELLULAR CARCINOMA AND USES THEREOF
PCT/EP2022/058188
This application discloses in vitro methods for the diagnosis, prognosis, and/or monitoring of cancer, in particular liver cancer or hepatocellular carcinoma (HCC) based on the aggregate expression level and oxidation level of all protein tyrosine phosphatases in a sample; whether or not in combination with the differential expression of protein tyrosine phosphatases individually. Also provided are in vitro methods for the selection of a prophylactic or therapeutic treatment or the evaluate the efficacy of a therapeutic treatment. Further, the present application provides a kit to be used in said methods.
Key advantages of the technology Proteomic assay enabling diagnosis and patient stratification of according to stage of transition from steatosis/NAFLD/NASH to HCC from human biopsies. Robust Mass-Spectrometry method enabling direct analysis of biopsy samples also conducive to the development of blood-based biomarker assays, including ELISA. Potential applications Proteomic assay enabling NAFLD/NASH/HCC diagnosis, prognosis and patient stratification for therapeutic treatment decision-making Companion diagnostic for assessing treatment efficacy including innovative approaches under clinical development Possible implementation as blood-based assay suitable for clinical settings
PCT patent application published on Oct 06th 2022 WO/2022/207588